世界の新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）市場予測（～2028年）：投与量別、0.5mlパッケージ、1mlパッケージ、2mlパッケージ、その他、接種材料種類別、初回ワクチン接種、再ワクチン接種

• 英文タイトル：Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

• レポートコード：GIR-22E8990 • 出版社/出版日：GlobalInfoResearch / 2022年5月 • レポート形態：英文、PDF、74ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界の新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・投与量別、0.5mlパッケージ、1mlパッケージ、2mlパッケージ、その他、接種材料種類別、初回ワクチン接種、再ワクチン接種 用途別セグメントは次のように区分されます。 ・0〜5歳、5〜18歳、18〜45歳、45〜65歳、65歳以上 世界の新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）市場の主要な市場プレーヤーは以下のとおりです。 ・Vakzine Projekt Management (VPM)、Serum Institute of India 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）メーカーの企業概要、2019年～2022年までの新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までの新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、および新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の産業チェーンを掲載しています。 ・第13、14、15章では、新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Vakzine Projekt Management (VPM)、Serum Institute of India ・メーカー別市場シェア ・地域別市場分析2017年-2028年 ・種類別分析2017年-2028年：投与量別、0.5mlパッケージ、1mlパッケージ、2mlパッケージ、その他、接種材料種類別、初回ワクチン接種、再ワクチン接種 ・用途別分析2017年-2028年：0〜5歳、5〜18歳、18〜45歳、45〜65歳、65歳以上 ・新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ ・新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア ・新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア ・新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の南米市場規模2017年-2028年：ブラジル、アルゼンチン ・新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. 0-5 Years Old accounting for % of the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 0.5ml Package segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 include Vakzine Projekt Management (VPM), Serum Institute of India, , , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
by Dosage
0.5ml Package
1ml Package
2ml Package
Other
by Type of Inoculator
Initial Vaccinate
Revaccination
Market segment by Application can be divided into
0-5 Years Old
5-18 Years Old
18-45 Years Old
45-65 Years Old
≥65 Years Old
The key market players for global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market are listed below:
Vakzine Projekt Management (VPM)
Serum Institute of India
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19, with price, sales, revenue and global market share of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 from 2019 to 2022.
Chapter 3, the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19.
Chapter 13, 14, and 15, to describe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 0.5ml Package
1.2.3 1ml Package
1.2.4 2ml Package
1.2.5 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 0-5 Years Old
1.3.3 5-18 Years Old
1.3.4 18-45 Years Old
1.3.5 45-65 Years Old
1.3.6 ≥65 Years Old
1.4 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size & Forecast
1.4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Value (2017 & 2021 & 2028)
1.4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume (2017-2028)
1.4.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price (2017-2028)
1.5 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Capacity Analysis
1.5.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Total Production Capacity (2017-2028)
1.5.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Drivers
1.6.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Restraints
1.6.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Trends Analysis
2 Manufacturers Profiles
2.1 Vakzine Projekt Management (VPM)
2.1.1 Vakzine Projekt Management (VPM) Details
2.1.2 Vakzine Projekt Management (VPM) Major Business
2.1.3 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product and Services
2.1.4 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Serum Institute of India
2.2.1 Serum Institute of India Details
2.2.2 Serum Institute of India Major Business
2.2.3 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product and Services
2.2.4 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Breakdown Data by Manufacturer
3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
3.4 Market Concentration Rate
3.4.1 Top 3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturer Market Share in 2021
3.4.2 Top 6 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturer Market Share in 2021
3.5 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Region
4.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Region (2017-2028)
4.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2017-2028)
4.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028)
4.3 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028)
4.4 Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028)
4.5 South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028)
4.6 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028)
5 Market Segment by Type
5.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Type (2017-2028)
5.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2028)
5.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Application (2017-2028)
6.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2028)
6.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028)
7.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028)
7.3 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country
7.3.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Country (2017-2028)
7.3.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028)
8.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028)
8.3 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country
8.3.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Country (2017-2028)
8.3.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028)
9.2 Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028)
9.3 Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Region
9.3.1 Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028)
10.2 South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028)
10.3 South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country
10.3.1 South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Country (2017-2028)
10.3.2 South America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028)
11.2 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028)
11.3 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country
11.3.1 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 and Key Manufacturers
12.2 Manufacturing Costs Percentage of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19
12.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Process
12.4 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Typical Distributors
13.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

---